Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $5.68.

  • Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) rose 155641.03% to $5.68 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.03, marking a year-over-year decrease of 1912.35%. This contributed to the annual value of -$0.22 for FY2024, which is 10727.55% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $5.68, which was up 155641.03% from $0.24 recorded in Q2 2025.
  • Ligand Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $5.68 during Q3 2025, with a 5-year trough of -$2.88 in Q2 2024.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was $0.24 (2025), whereas its average is $0.59.
  • Per our database at Business Quant, Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) plummeted by 231538.46% in 2024 and then surged by 155641.03% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.13 in 2021, then plummeted by 35.72% to -$0.17 in 2022, then soared by 688.75% to $1.03 in 2023, then crashed by 265.02% to -$1.7 in 2024, then skyrocketed by 434.17% to $5.68 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $5.68 for Q3 2025, versus $0.24 for Q2 2025 and -$2.21 for Q1 2025.